{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T23:46:41Z","timestamp":1793317601503,"version":"4.5.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2021,1,2]],"date-time":"2021-01-02T00:00:00Z","timestamp":1609545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,1,2]],"date-time":"2021-01-02T00:00:00Z","timestamp":1609545600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Calcif Tissue Int"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1007\/s00223-020-00785-1","type":"journal-article","created":{"date-parts":[[2021,1,2]],"date-time":"2021-01-02T14:02:38Z","timestamp":1609596158000},"page":"587-594","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Comparative Effect of Zoledronate at 6 Versus 18 Months Following Denosumab Discontinuation"],"prefix":"10.1007","volume":"108","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9624-6296","authenticated-orcid":false,"given":"Athanasios D.","family":"Anastasilakis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9232-4042","authenticated-orcid":false,"given":"Stergios A.","family":"Polyzos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6501-3692","authenticated-orcid":false,"given":"Maria P.","family":"Yavropoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5035-127X","authenticated-orcid":false,"given":"Natasha M.","family":"Appelman-Dijkstra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charikleia","family":"Ntenti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stylianos","family":"Mandanas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athanasios","family":"Papatheodorou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3231-3357","authenticated-orcid":false,"given":"Polyzois","family":"Makras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,2]]},"reference":[{"key":"785_CR1","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1007\/s11914-019-00502-4","volume":"17","author":"O Lamy","year":"2019","unstructured":"Lamy O, Stoll D, Aubry-Rozier B, Rodriguez EG (2019) Stopping denosumab. Curr Osteoporos Rep 17:8\u201315","journal-title":"Curr Osteoporos Rep"},{"key":"785_CR2","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1002\/jbmr.3110","volume":"32","author":"AD Anastasilakis","year":"2017","unstructured":"Anastasilakis AD, Polyzos SA, Makras P, Aubry-Rozier B, Kaouri S, Lamy O (2017) Clinical features of 24 patients with rebound-associated vertebral fractures after denosumab discontinuation: systematic review and additional cases. J Bone Miner Res 32:1291\u20131296","journal-title":"J Bone Miner Res"},{"key":"785_CR3","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/S2213-8587(17)30138-9","volume":"5","author":"HG Bone","year":"2017","unstructured":"Bone HG, Wagman RB, Brandi ML et al (2017) 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol 5:513\u2013523","journal-title":"Lancet Diabetes Endocrinol"},{"key":"785_CR4","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1002\/jbmr.3337","volume":"33","author":"SR Cummings","year":"2018","unstructured":"Cummings SR, Ferrari S, Eastell R et al (2018) Vertebral fractures after discontinuation of denosumab: a post hoc analysis of the randomized placebo-controlled FREEDOM trial and its extension. J Bone Miner Res 33:190\u2013198","journal-title":"J Bone Miner Res"},{"key":"785_CR5","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1007\/s00198-017-3919-1","volume":"28","author":"MR McClung","year":"2017","unstructured":"McClung MR, Wagman RB, Miller PD, Wang A, Lewiecki EM (2017) Observations following discontinuation of long-term denosumab therapy. Osteoporos Int 28:1723\u20131732","journal-title":"Osteoporos Int"},{"key":"785_CR6","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1530\/EJE-16-1027","volume":"176","author":"AD Anastasilakis","year":"2017","unstructured":"Anastasilakis AD, Yavropoulou MP, Makras P, Sakellariou GT, Papadopoulou F, Gerou S, Papapoulos SE (2017) Increased osteoclastogenesis in patients with vertebral fractures following discontinuation of denosumab treatment. Eur J Endocrinol 176:677\u2013683","journal-title":"Eur J Endocrinol"},{"key":"785_CR7","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.bone.2017.08.003","volume":"105","author":"E Tsourdi","year":"2017","unstructured":"Tsourdi E, Langdahl B, Cohen-Solal M, Aubry-Rozier B, Eriksen EF, Guanabens N, Obermayer-Pietsch B, Ralston SH, Eastell R, Zillikens MC (2017) Discontinuation of denosumab therapy for osteoporosis: a systematic review and position statement by ECTS. Bone 105:11\u201317","journal-title":"Bone"},{"key":"785_CR8","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1002\/jbmr.3853","volume":"34","author":"AD Anastasilakis","year":"2019","unstructured":"Anastasilakis AD, Papapoulos SE, Polyzos SA, Appelman-Dijkstra NM, Makras P (2019) Zoledronate for the prevention of bone loss in women discontinuing denosumab treatment. a prospective 2-year clinical trial. J Bone Miner Res 34:2220\u20132228","journal-title":"J Bone Miner Res"},{"key":"785_CR9","doi-asserted-by":"publisher","first-page":"115478","DOI":"10.1016\/j.bone.2020.115478","volume":"138","author":"P Makras","year":"2020","unstructured":"Makras P, Papapoulos SE, Polyzos SA, Appelman-Dijkstra NM, Anastasilakis AD (2020) The three-year effect of a single zoledronate infusion on bone mineral density and bone turnover markers following denosumab discontinuation in women with postmenopausal osteoporosis. Bone 138:115478","journal-title":"Bone"},{"key":"785_CR10","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.4098","author":"AS Solling","year":"2020","unstructured":"Solling AS, Harslof T, Langdahl B (2020) Treatment with zoledronate subsequent to denosumab in osteoporosis: a randomized trial. J Bone Miner Res. https:\/\/doi.org\/10.1002\/jbmr.4098","journal-title":"J Bone Miner Res"},{"key":"785_CR11","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1002\/jbmr.3962","volume":"35","author":"J Everts-Graber","year":"2020","unstructured":"Everts-Graber J, Reichenbach S, Ziswiler HR, Studer U, Lehmann T (2020) A Single infusion of zoledronate in postmenopausal women following denosumab discontinuation results in partial conservation of bone mass gains. J Bone Miner Res 35:1207\u20131215","journal-title":"J Bone Miner Res"},{"key":"785_CR12","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1007\/s00223-017-0288-x","volume":"101","author":"IR Reid","year":"2017","unstructured":"Reid IR, Horne AM, Mihov B, Gamble GD (2017) Bone loss after denosumab: only partial protection with zoledronate. Calcif Tissue Int 101:371\u2013374","journal-title":"Calcif Tissue Int"},{"key":"785_CR13","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1359\/jbmr.1997.12.4.624","volume":"12","author":"S Gonnelli","year":"1997","unstructured":"Gonnelli S, Cepollaro C, Pondrelli C, Martini S, Monaco R, Gennari C (1997) The usefulness of bone turnover in predicting the response to transdermal estrogen therapy in postmenopausal osteoporosis. J Bone Miner Res 12:624\u2013631","journal-title":"J Bone Miner Res"},{"key":"785_CR14","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/s002239900713","volume":"65","author":"S Gonnelli","year":"1999","unstructured":"Gonnelli S, Cepollaro C, Pondrelli C, Martini S, Montagnani A, Monaco R, Gennari C (1999) Bone turnover and the response to alendronate treatment in postmenopausal osteoporosis. Calcif Tissue Int 65:359\u2013364","journal-title":"Calcif Tissue Int"},{"key":"785_CR15","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1172\/JCI113725","volume":"82","author":"R Civitelli","year":"1988","unstructured":"Civitelli R, Gonnelli S, Zacchei F, Bigazzi S, Vattimo A, Avioli LV, Gennari C (1988) Bone turnover in postmenopausal osteoporosis. Effect of calcitonin treatment. J Clin Invest 82:1268\u20131274","journal-title":"J Clin Invest"},{"key":"785_CR16","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1056\/NEJMoa067312","volume":"356","author":"DM Black","year":"2007","unstructured":"Black DM, Delmas PD, Eastell R et al (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356:1809\u20131822","journal-title":"N Engl J Med"},{"key":"785_CR17","doi-asserted-by":"publisher","DOI":"10.7326\/M20-0882","author":"H Lyu","year":"2020","unstructured":"Lyu H, Yoshida K, Zhao SS, Wei J, Zeng C, Tedeschi SK, Leder BZ, Lei G, Tang P, Solomon DH (2020) Delayed denosumab injections and fracture risk among patients with osteoporosis: a population-based cohort study. Ann Intern Med. https:\/\/doi.org\/10.7326\/M20-0882","journal-title":"Ann Intern Med"},{"key":"785_CR18","doi-asserted-by":"publisher","DOI":"10.7326\/M20-4802","author":"KE Ensrud","year":"2020","unstructured":"Ensrud KE, Schousboe JT (2020) Delayed denosumab injections and fracture risk. Ann Intern Med. https:\/\/doi.org\/10.7326\/M20-4802","journal-title":"Ann Intern Med"},{"key":"785_CR19","doi-asserted-by":"publisher","DOI":"10.7326\/M20-4802","author":"E Tsourdi","year":"2020","unstructured":"Tsourdi E, Zillikens MC, Meier C et al (2020) Fracture risk and management of discontinuation of denosumab therapy: a systematic review and position statement by ECTS. J Clin Endocrinol Metab. https:\/\/doi.org\/10.7326\/M20-4802","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Calcified Tissue International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00223-020-00785-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00223-020-00785-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00223-020-00785-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,25]],"date-time":"2021-04-25T03:25:29Z","timestamp":1619321129000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00223-020-00785-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,2]]},"references-count":19,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["785"],"URL":"https:\/\/doi.org\/10.1007\/s00223-020-00785-1","relation":{},"ISSN":["0171-967X","1432-0827"],"issn-type":[{"value":"0171-967X","type":"print"},{"value":"1432-0827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,2]]},"assertion":[{"value":"29 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 November 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Athanasios D. Anastasilakis has received lecture fees from Amgen; Natasha M Appelman-Dijkstra has served on the national advisory board for Prolia and has received lecture fees from Amgen; Polyzois Makras has received lecture fees and research grants from Amgen; Stergios A. Polyzos, Maria P. Yavropoulou, Charikleia Ntenti, Stylianos Mandanas and Athanasios Papatheodorou have nothing to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Medical Ethical Committees of the 424 General Military Hospital and the 251 Hellenic Air Force & VA General Hospital\u00a0and it was performed in accordance with the ethical standards as laid down in the 1964 declaration of Helsinki and its later amendments. All patients provided informed consent for their participation and publication of their results.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}